Nucleocytoplasmic transport in gynaecological cancer: From mechanisms to therapeutic potential (Review)
Authors:
Open Access
- 8 October 2026
- journal article
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 69 (5) , 1-20
Abstract
Proper localization of proteins and RNAs in a cell is crucial for physiological function and cellular homeostasis, while disruption of the nucleocytoplasmic transport machinery leads to carcinogenesis. In gynaecological (endometrial, cervical and ovarian) tumours, upregulated nuclear transport protein expression promotes malignant cell proliferation, invasion and resistance to therapy. Therefore, therapeutic targeting of nuclear transport proteins has emerged as a promising anticancer approach. Researchers have extensively studied both nuclear import and export inhibitors in preclinical settings, alone or in combination with other targeted therapy agents. However, to date, only one compound, the exportin 1 inhibitor Selinexor, has been approved for cancer treatment. The development of nuclear transport inhibition‑based therapies is hindered by limited inhibitor specificity and complex cellular resistance mechanisms. The aim of the present review was to clarify the connection between nuclear transport dysregulation, hallmarks of gynaecological tumours and the challenges of inhibiting nuclear transport in gynaecological cancer treatment.Keywords
This publication has 190 references indexed in Scilit:
- A Tale of Two Mechanisms: The p53 Modulator COTI‐2 Is a Zn MetallochaperoneDrug Development Research, 2026
- KPNA5 Suppresses Malignant Progression of Ovarian Cancer Through Importing the PTPN4 Into the NucleusCancer Medicine, 2025
- Importin subunit beta‐1 mediates ERK5 nuclear translocation, and its inhibition synergizes with ERK5 kinase inhibitors in reducing cancer cell proliferationMolecular Oncology, 2024
- The nuclear export protein exportin‐1 in solid malignant tumours: From biology to clinical trialsClinical and Translational Medicine, 2024
- Exportin 1‐mediated nuclear/cytoplasmic trafficking controls drug sensitivity of classical Hodgkin's lymphomaMolecular Oncology, 2023
- Nuclear transport proteins are secreted by cancer cells and identified as potential novel cancer biomarkersInternational Journal of Cancer, 2021
- Metabolic factors contribute to T‐cell inhibition in the ovarian cancer ascitesInternational Journal of Cancer, 2020
- Juvenile myelomonocytic leukemia with t(7;11)(p15;p15) and NUP98‐HOXA11 fusionAmerican Journal of Hematology, 2009
- The Karyopherin proteins, Crm1 and Karyopherin β1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferationInternational Journal of Cancer, 2009
- Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancerCancer, 2008